Loading…
Details
- Instance of
- type of disease
- Subclass of
- myeloproliferative neoplasm, primary polycythemia
- described by source
- Great Soviet Encyclopedia (1926–1947)
- drug or therapy used for treatment
- uracil mustard, busulfan, pipobroman, anagrelide, hydroxycarbamide, ruxolitinib, peginterferon alfa-2a, pipobroman
- health specialty
- hematology
- ICD-9-CM
- 238.4
- nickname
- Վակեզի հիվանդություն, Էրիթրեմիա
Connected on Wikidata
Subject of
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
- Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
- Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
- Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
- Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
- Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
- Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
- A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
- Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
- KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor
Nothing in the MetaHistoryBook collection references this item yet.